

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 6 : C07D 211/60, 401/12, 401/14, A61K 31/44, 31/445, C07C 271/54, 275/34, C07D 213/30, A61K 31/47, 31/17, C07D 213/65, 215/20, A61K 31/27</p>	A1	<p>(11) International Publication Number: WO 95/26337 (43) International Publication Date: 5 October 1995 (05.10.95)</p>
<p>(21) International Application Number: PCT/US95/03716 (22) International Filing Date: 23 March 1995 (23.03.95) (30) Priority Data: 08/218,120 25 March 1994 (25.03.94) US 08/377,283 23 January 1995 (23.01.95) US (71) Applicant: VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 40 Allston Street, Cambridge, MA 02139 (US). (72) Inventors: ZELLE, Robert, Edward; 67 Boon Road, Stow, MA 01775 (US). HARDING, Matthew, W.; 171 Willow Street, Acton, MA 01720 (US). (74) Agents: HALEY, James, F., Jr. et al.; Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020 (US).</p>		<p>(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: NOVEL CARBAMATES AND UREAS AS MODIFIERS OF MULTI-DRUG RESISTANCE (57) Abstract The present invention relates to compounds as represented by formula (I) that can maintain, increase, or restore sensitivity of cells to therapeutic or prophylactic agents. This comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well-suited for treatment of multi-drug resistant cells, for prevention of the development of multi-drug resistance, and for use in multi-drug resistant cancer therapy.</p> <div style="text-align: center;"> <p>(I)</p> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

NOVEL CARBAMATES AND UREAS AS
MODIFIERS OF MULTI-DRUG RESISTANCE

TECHNICAL FIELD OF THE INVENTION

5 The present invention relates to novel
compounds which can maintain, increase, or restore
sensitivity of cells to therapeutic or prophylactic
agents. This invention also relates to pharmaceutical
compositions comprising these compounds. The compounds
and pharmaceutical compositions of this invention are
10 particularly well-suited for treatment of multi-drug
resistant cells, for prevention of the development of
multi-drug resistance and for use in multi-drug
resistant cancer therapy.

BACKGROUND OF THE INVENTION

15 A major problem affecting the efficacy of
chemotherapy regimens is the evolution of cells which,
upon exposure to a chemotherapeutic drug, become
resistant to a multitude of structurally unrelated
drugs and therapeutic agents. The appearance of such
20 multi-drug resistance often occurs in the presence of
overexpression of the 170-kDA membrane P-glycoprotein
(gp-170). The gp-170 protein is present in the plasma
membranes of some healthy tissues, in addition to
cancer cell lines, and is homologous to bacterial
25 transport proteins (Hait et al., Cancer Communications,
Vol. 1(1), 35 (1989); West, TIBS, Vol. 15, 42 (1990)).
The protein acts as an export pump, conferring drug
resistance through active extrusion of toxic chemicals.
Although the mechanism for the pump is unknown, it is

- 2 -

speculated that the gp-170 protein functions by expelling substances that share certain chemical or physical characteristics, such as hydrophobicity, the presence of carbonyl groups, or the existence of a glutathione conjugate (see West).

Recently, another protein responsible for multidrug resistance, MRP (multidrug resistance associated protein), was identified in H69AR cells, an MDR cell line that lacks detectable P-glycoprotein [S. P. C. Cole et al., Science, 258, pp. 1650-54 (1992)]. MRP has also been detected in other non-P-glycoprotein MDR cell lines, such as HL60/ADR and MCF-7 breast carcinoma cells [(E. Schneider et al., Cancer Res., 54, pp. 152-58 (1994); and N. Krishnamachary et al., Cancer Res., 53, pp. 3658-61 (1993)]].

The MRP gene encodes a 190 kD membrane-associated protein that is another member of the ATP binding cassette superfamily. MRP appears to function in the same manner as P-glycoprotein, acting as a pump for removing natural product drugs from the cell. A possible physiological function for MRP maybe ATP-dependent transport of glutathione S-conjugates [G. Jedlitschky et al., Cancer Res., 54, pp. 4833-36 (1994); I. Leier et al., J. Biol. Chem., 269, pp. 27807-10 (1994); and Muller et al., Proc. Natl. Acad. Sci. USA, 91, pp. 13033-37 (1994)].

The role of MRP in clinical drug resistance remains to be clearly defined, but it appears likely that MRP may be another protein responsible for a broad resistance to anti-cancer drugs.

Various chemical agents have been administered to repress multi-drug resistance and restore drug sensitivity. While some drugs have improved the responsiveness of multi-drug resistant ("MDR") cells to chemotherapeutic agents, they have often been

- 3 -

accompanied by undesirable clinical side effects (see Hait et al.). For example, although cyclosporin A ("CsA"), a widely accepted immunosuppressant, can sensitize certain carcinoma cells to chemotherapeutic agents (Slater et al., Br. J. Cancer, Vol. 54, 235 (1986)), the concentrations needed to achieve that effect produce significant immunosuppression in patients whose immune systems are already compromised by chemotherapy (see Hait et al.). In addition, CsA usage is often accompanied by adverse side effects including nephrotoxicity, hepatotoxicity and central nervous system disorders. Similarly, calcium transport blockers and calmodulin inhibitors both sensitize MDR cells, but each produces undesirable physiological effects (see Hait et al.; Twentyman et al., Br. J. Cancer, Vol. 56, 55 (1987)).

Recent developments have led to agents said to be of potentially greater clinical value in the sensitization of MDR cells. These agents include analogs of CsA which do not exert an immunosuppressive effect, such as 11-methyl-leucine cyclosporin (11-met-leu CsA) (see Hait et al.; Twentyman et al.), or agents that may be effective at low doses, such as the immunosuppressant FK-506 (Epand and Epand, Anti-Cancer Drug Design 6, 189 (1991)). Despite these developments, the need remains for effective agents which may be used to resensitize MDR cells to therapeutic or prophylactic agents or to prevent the development of multi-drug resistance.

30

SUMMARY OF THE INVENTION

The present invention provides novel compounds that are useful to maintain, increase or restore drug sensitivity in multi-drug resistant ("MDR") cells, compositions containing those compounds


- 4 -

and methods for using them. The compounds of this invention may be used alone or in combination with other therapeutic or prophylactic agents to maintain, increase or restore the therapeutic or prophylactic effects of drugs in cells, especially MDR cells, or to prevent the development of MDR cells. According to one embodiment of this invention, these novel compounds, compositions and methods are advantageously used to aid or enhance chemotherapy regimens for the treatment or prophylaxis of cancer and other diseases.

The present invention also provides methods for preparing the compounds of this invention and intermediates useful in those methods.

DETAILED DESCRIPTION OF THE INVENTION

This invention relates to a novel class of compounds represented by formula (I):



wherein A is CH₂, oxygen, NH or N-(C1-C4 alkyl);
wherein B and D are independently:

Ar, (C1-C6)-straight or branched alkyl,
(C2-C6)-straight or branched alkenyl or alkynyl,
(C5-C7)-cycloalkyl substituted (C1-C6)-straight or
branched alkyl, (C3-C6)-straight or branched alkenyl or
alkynyl, (C5-C7)-cycloalkenyl substituted
(C1-C6)-straight or branched alkyl, (C3-C6)-straight or
branched alkenyl or alkynyl, Ar-substituted

- 5 -

(C1-C6)-straight or branched alkyl, Ar-substituted

(C3-C6)-straight or branched alkenyl or alkynyl,

wherein any one of the CH₂ groups of said
alkyl chains may be optionally replaced by a heteroatom
5 selected from the group consisting of O, S, SO, SO₂,
and NR, wherein R is selected from the group consisting
of hydrogen, (C1-C4)-straight or branched alkyl, (C3-
C4)-straight or branched alkenyl or alkynyl, and (C1-
C4) bridging alkyl wherein a bridge is formed between
10 the nitrogen and a carbon atom of said heteroatom-
containing chain to form a ring, and wherein said ring
is optionally fused to an Ar group;

J is selected from the group consisting of
hydrogen, (C1-C6)-straight or branched alkyl, (C3-C6)-
15 straight or branched alkenyl and -CH₂Ar;

K is selected from the group consisting of
(C1-C4)-straight or branched alkyl, -CH₂Ar and
cyclohexylmethyl;

or J and K may be taken together to form a
20 5-7 membered heterocyclic ring which may contain a
heteroatom selected from the group consisting of O, S,
SO and SO₂;

Z is O or S;

Y is O or N, wherein

25 when Y is O, then R₁ is a lone pair (as
used herein, the term "lone pair" refers to a lone pair
of electrons, such as the lone pair of electrons
present on divalent oxygen) and R₂ is selected from the
group consisting of Ar, (C1-C6)-straight or branched
30 alkyl, and (C3-C6)-straight or branched alkenyl or
alkynyl; and

when Y is N, then R₁ and R₂ are
independently selected from the group consisting of Ar,
(C1-C6)-straight or branched alkyl, and (C3-C6)-
35 straight or branched alkenyl or alkynyl; or R₁ and R₂

- 6 -

are taken together to form a heterocyclic 5-6 membered ring selected from the group consisting of pyrrolidine, imidazolidine, pyrazolidine, piperidine, and piperazine;

5 wherein Ar is a carbocyclic aromatic group selected from the group consisting of phenyl, 1-naphthyl, 2-naphthyl, indenyl, azulenyl, fluorenyl, and anthracenyl;

10 or a heterocyclic aromatic group selected from the group consisting of 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, 2-pyrazolinyl, pyrazolidinyl, isoxazolyl, isotriazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, 1,3,4-thiadiazolyl, 15 pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, 1,3,5-trithianyl, indolizinyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furanyl, benzo[b]thiophenyl, 1H-indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H-quinolizinyl, quinolinyl, 1,2,3,4- 20 tetrahydro-quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydro-isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, and phenoxazinyl;

25 wherein Ar may contain one or more substituents which are independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, -SO₃H, trifluoromethyl, trifluoromethoxy, (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, 30 O-[(C1-C6)-straight or branched alkyl], O-[(C3-C4)-straight or branched alkenyl], O-benzyl, O-phenyl, 1,2-methylenedioxy, -NR₂R₄, carboxyl, N-(C1-C5-straight or branched alkyl or C3-C5-straight or branched alkenyl) carboxamides, N,N-di-(C1-C5-straight 35 or branched alkyl or C3-C5-straight or branched

- 7 -

alkenyl) carboxamides, morpholinyl, piperidinyl, O-X, $\text{CH}_2-(\text{CH}_2)_q\text{-X}$, $\text{O}-(\text{CH}_2)_q\text{-X}$, $(\text{CH}_2)_q\text{-O-X}$, and CH=CH-X ;

wherein R_3 and R_4 are independently selected from the group consisting of (C1-C6)-straight or branched alkyl, (C3-C6)-straight or branched alkenyl, hydrogen and benzyl; or wherein R_3 and R_4 can be taken together to form a 5-6 membered heterocyclic ring such as, for example, piperidinyl, morpholinyl or pyrrolidinyl, X is selected from the group consisting of 4-methoxyphenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrazyl, quinolyl, 3,5-dimethylisoxazoyl, isoxazoyl, 2-methylthiazoyl, thiazoyl, 2-thienyl, 3-thienyl, and pyrimidyl; q is 0-2; and

n is 0 or 1.

As used herein for R_3 and R_4 , the term "heterocyclic" refers to a stable 5-6 membered monocycle or 8-11 membered bicyclic heterocycle which is either saturated or unsaturated, and which may be optionally benzofused if monocyclic. Each heterocycle consists of carbon atoms and from one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. As used herein, the terms "nitrogen and sulfur heteroatoms" include any oxidized form of nitrogen and sulfur, and the quaternized form of any basic nitrogen. The heterocyclic ring may be attached by any heteroatom of the cycle which results in the creation of a stable structure. Typical examples of such heterocycles include piperidinyl, morpholinyl or pyrrolidinyl.

Preferably, at least one of B or D is independently a straight chain terminated by an aryl group, i.e., a group represented by the formula -

$(\text{CH}_2)_r\text{-(X)}-(\text{CH}_2)_s\text{-Ar}$, wherein

r is 1-4;

s is 0-1;

- 8 -



Ar is as defined above; and

each X is independently selected from the group consisting of CH₂, O, S, SO, SO₂, and NR, wherein R is selected from the group consisting of hydrogen, (C1-C4)-straight or branched alkyl, (C3-C4)-straight or branched alkenyl or alkynyl, and (C1-C4) bridging alkyl wherein a bridge is formed between the nitrogen atom and the Ar group.



The preferred Ar groups of this invention include phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, indolyl, isoindolyl, quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, and 1,2,3,4-tetrahydroquinolinyl, wherein the Ar groups may contain one or more substituents which are independently selected from the group consisting of hydrogen, hydroxyl, nitro, trifluoromethyl, (C1-C6)-straight or branched alkyl, O-[(C1-C6)-straight or branched alkyl], halogen, SO₃H, and NR₃R₄, wherein R₃ and R₄ are independently selected from the group consisting of (C1-C6)-straight or branched alkyl, (C3-C6)-straight or branched alkenyl, hydrogen and benzyl; or wherein R₃ and R₄ can be taken together to form a 5-6 membered heterocyclic ring such as, for example, piperidinyl, morpholinyl or pyrrolidinyl.

Examples of some preferred compounds of formula (I), wherein J and K are taken together to form a 5-7 membered heterocyclic ring, have the formula (II) or (III), wherein Y, R₁ and R₂ are as defined above for formula (I), Ar is defined as above for preferred Ar groups and w is 1 or 2.

- 9 -



Examples of some preferred compounds of formula (I), wherein J is independently hydrogen, (C1-C6) straight or branched alkyl or (C3-C6) straight or branched alkenyl, have the formula (II') or (III'), wherein Y, R₁ and R₂ are as defined above for formula (I) and Ar is as defined above for preferred Ar groups and w is 1 or 2.



As used herein, the compounds of this invention, including the compounds of formula (I), are defined to include pharmaceutically acceptable derivatives thereof. A "pharmaceutically acceptable derivative" denotes any pharmaceutically acceptable salt, ester, or salt of such ester, of a compound of this invention or any other compound which, upon administration to a patient, is capable of providing (directly or indirectly) a compound of this invention, or a metabolite or residue thereof, characterized by the ability to maintain, increase or restore sensitivity of MDR cells to therapeutic or prophylactic

- 10 -

agents or to prevent development of multi-drug resistance.

Compounds of this invention, including those represented by formula (I), may be obtained using any conventional technique. Preferably, these compounds are chemically synthesized from readily available starting materials, such as alpha-amino acids. Modular and convergent methods for the synthesis of these compounds are also preferred. In a convergent approach, for example, large sections of the final product are brought together in the last stages of the synthesis, rather than by incremental addition of small pieces to a growing molecular chain.

Scheme 1 illustrates a representative example of a convergent process for the synthesis of compounds of formula (I'), a preferred subset of compounds of formula (I), wherein A and Z are oxygens. The process comprises esterification of a protected alpha-amino acid of formula (X), wherein P is a protecting group, with an alcohol of formula (XI). Protected alpha-amino acids are well known in the art and many are commercially available. For example, common protecting groups and convenient methods for the protection of amino acids are described in T. W. Greene, P. G. M. Wuts, Protective Groups in Organic Chemistry, 2nd Ed., John Wiley and Sons, New York (1991). Alkoxycarbonyl groups are preferred for protection of the nitrogen atom in compounds of formula (X), with t-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), allyloxycarbonyl (Alloc), and trimethylsilylethoxycarbonyl (Teoc) being more preferred.

After esterification, compounds of formula (XII) are deprotected under suitable deprotection conditions (see Greene, supra), and the free amino group of (XIII) is then acylated using a preformed acyl


- 11 -

chloride of formula (XIV) to give a compound of formula (I'). The halogen chloro group in (XIV) may be replaced with other leaving groups or activating groups known in the art such as other halogens, imidazolyl or pentafluorophenoxy groups.


Alcohols of formula (XI) wherein m is 0 (XI') can also be conveniently prepared, for example, as illustrated in Schemes 2 and 3. Reaction of an organometallic reagent of formula (XV) and an aldehyde of formula (XVI) provides alcohols of formula (XI') (Scheme 2).

Alternatively (Scheme 3), 1,6-heptadiyn-4-ol can be coupled via a metal-catalyzed reaction to aromatic halides of formula (XVII) to give an alcohol of formula (XVIII). Subsequent hydrogenation provides an alcohol of formula (XI''), a preferred subset of alcohols of formula (XI).


Scheme 1



Scheme 2



Scheme 3



5 Thus, this invention also provides a method
for preparing compounds of formula (I') comprising the
steps of:

10 (a) esterifying a protected amino acid of formula (X) with an alcohol of formula (XI) to give an intermediate of formula (XII);

(b) deprotecting the amino protecting group in the intermediate of formula (XII) to give an amino ester of formula (XIII); and

(c) acylating the free amino group in the compound of formula (XIII) with an acyl halide of formula (XIV) or other activated derivatives thereof.

It should be appreciated by those of ordinary skill in the art that a large variety of compounds of formula (I) may be readily prepared, according to the processes illustrated in synthetic Schemes 1 and 2.

- 13 -

The same processes may be used for the synthesis of many different end-products, by altering the variables in the starting materials.

5 Optically active compounds of formula (I) may also be prepared using optically active starting materials, thus obviating the need for resolution of enantiomers or separation of diastereomers at a late stage in the synthesis.

10 It will also be appreciated by those of ordinary skill in the art that the above synthetic schemes are not intended to comprise a comprehensive list of all means by which the compounds or the intermediates of this invention may be synthesized. Further methods or modifications of the above general
15 schemes will be evident to those of ordinary skill in the art.

 The compounds of this invention may be modified by appending appropriate functionalities to enhance selective biological properties. Such
20 modifications are known in the art and include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by
25 injection, alter metabolism and alter rate of excretion.

 The compounds of this invention are characterized by the ability to increase, restore or maintain the sensitivity of MDR cells to cytotoxic
30 compounds, such as, for example, those typically used in chemotherapy. Based on that ability, the compounds of this invention are advantageously used as chemosensitizing agents, to increase the effectiveness of chemotherapy in individuals who are afflicted with
35 drug-resistant cancers, tumors, metastases or disease.

- 14 -

In addition, the compounds of this invention are capable of maintaining sensitivity to therapeutic or prophylactic agents in non-resistant cells. Therefore, the compounds of this invention are useful in treating or preventing multi-drug resistance in a patient. More specifically, these compounds are useful in treating or preventing P-glycoprotein-mediated MDR and MRP-mediated MDR.

As used throughout this application, the term "patient" refers to mammals, including humans. And the term "cell" refers to mammalian cells, including human cells.

As used herein, the terms "sensitizing agent", "sensitizer", "chemosensitizing agent", "chemosensitizer" and "MDR modifier" denote a compound having the ability to increase or restore the sensitivity of an MDR cell, or to maintain the sensitivity of a non-resistant cell, to one or more therapeutic or prophylactic agents. The term "MDR sensitization" and "sensitization" and "resensitization" refer to the action of such a compound in maintaining, increasing, or restoring drug sensitivity.

According to one embodiment of this invention, compounds that are useful in increasing, restoring or maintaining drug sensitivity are also capable of binding to the protein FKBP-12 or other related FK-506 binding proteins such as FKBP-13, FKBP-26 and FKBP-52. In vitro tests (data not shown) of these compounds demonstrate that the agents bind to FKBP-12. Thus, this invention also comprises a class of chemosensitizing agents other than FK-506, characterized by the ability to bind to the FK binding protein-12 or related FK binding proteins, pharmaceutical compositions including such agents and a physiologically acceptable adjuvant, carrier or

- 15 -

vehicle, and methods of using those compositions for treating or preventing multi-drug resistance in a patient.

The compounds of the present invention may be used in the form of pharmaceutically acceptable salts derived from inorganic or organic acids and bases. Included among such acid salts are the following: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenyl-propionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate and undecanoate. Base salts include ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth metal salts, such as calcium and magnesium salts, salts with organic bases, such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides, such as benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.

- 16 -

The compounds of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir in dosage formulations containing conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.

The pharmaceutical compositions of this invention comprise any of the compounds of the present invention, or pharmaceutically acceptable salts thereof, with any pharmaceutically acceptable carrier, adjuvant or vehicle. Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

According to this invention, the pharmaceutical compositions may be in the form of a sterile injectable preparation, for example a sterile injectable aqueous or oleaginous suspension. This

- 17 -

suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as do natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as Ph. Hely or similar alcohol.

The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.

- 18 -

Alternatively, the pharmaceutical compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a
5 suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

10 The pharmaceutical compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower
15 intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.

Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema
20 formulation. Topically-transdermal patches may also be used.

For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved
25 in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying
30 wax and water. Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not
35 limited to, mineral oil, sorbitan monostearate,

- 19 -

polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

For ophthalmic use, the pharmaceutical compositions may be formulated as micronized
5 suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be
10 formulated in an ointment such as petrolatum.

The pharmaceutical compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical
15 formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.

20 The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated, and the particular mode of administration. It should be understood, however, that a specific dosage and
25 treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination,
30 and the judgment of the treating physician and the severity of the particular disease being treated. The amount of active ingredient may also depend upon the therapeutic or prophylactic agent, if any, with which the ingredient is co-administered. The term
35 "pharmaceutically effective amount" refers to an amount

- 20 -

effective to prevent multi-drug resistance or maintain, increase or restore drug sensitivity in MDR cells.

Dosage levels of between about 0.01 and about 100 mg/kg body weight per day, preferably between about 0.5 and about 50 mg/kg body weight per day of the active ingredient compound are useful. A typical preparation will contain between about 5% and about 95% active compound (w/w). Preferably, such preparations contain between about 20% and about 80% active compound.

When the compounds of this invention are administered in combination therapies with other agents, they may be administered sequentially or concurrently to the patient. Alternatively, pharmaceutical or prophylactic compositions according to this invention may comprise a combination of a compound of this invention and another therapeutic or prophylactic agent.

For example, the compounds may be administered either alone or in combination with one or more therapeutic agents, such as chemotherapeutic agents, (e.g., actinomycin D, doxorubicin, vincristine, vinblastine, etoposide, amsacrine, mitoxantrone, tenipaside, taxol and colchicine) and/or a chemosensitizing agent (e.g., cyclosporin A and analogs, phenothiazines and thioxantheres), in order to increase the susceptibility of the MDR cells within the patient to the agent or agents.

In order that this invention may be more fully understood, the following examples are set forth. These examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention in any way.

- 21 -

ExamplesGeneral Methods

- Proton nuclear magnetic resonance (^1H NMR) spectra were recorded at 500 MHz on a Bruker AMX 500.
- 5 Chemical shifts are reported in parts per million (δ) relative to Me_4Si (δ 0.0). Analytical high performance liquid chromatography was performed on either a Waters 600E or a Hewlett Packard 1050 liquid chromatograph.

Example 1

- 10 1,7-Dipyridin-3-yl-hept-1,6-diyne-4-ol (1): A mixture of 1,6-heptadiyn-4-ol (25 g, 0.231 mol), palladium(II) acetate (2.6 g, 11.0 mmol), copper(I)iodide (3.3 g, 11.0 mmol) and triphenylphosphine (9.1 g, 35.0 mmol) in degassed triethylamine (300 mL) was treated with 3-
- 15 bromopyridine (77 g, 0.49 mol). After stirring for 24 h at room temperature, the reaction was filtered through a plug of Celite and the Celite washed with ethyl acetate (EtOAc). The filtrate was concentrated to afford a dark brown oil. This material was
- 20 dissolved in 2 N hydrochloric acid (HCl) and washed with EtOAc (2x). The pH of the aqueous layer was adjusted to pH>8 by addition of 3 N sodium hydroxide (NaOH) and then extracted with EtOAc (2x). The
- 25 extracts were combined, washed with half-saturated aqueous sodium chloride, brine, dried over magnesium sulfate (MgSO_4), filtered and concentrated. The residue was passed through a plug of silica gel (SiO_2 , elution with EtOAc) to provide 33.1 g of compound 1 as a solid upon drying.

Example 2

- 30 1,7-Dipyridin-3-yl-heptan-4-ol (2): A suspension of platinum oxide (280 mg) in absolute ethanol (1 mL) was diluted with absolute methanol (10 mL) followed by the

- 22 -

addition of compound 1 (2.81 g, 10.73 mmol). The suspension was placed under 40 psi of hydrogen gas. After hydrogen consumption ceased, the hydrogen was replaced with nitrogen and the reaction was filtered and concentrated to provide 2.87 g of compound 2 as a viscous oil.

Example 3

(S)-Piperidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-(1-(3-pyridin-3-yl-propyl)-4-pyridin-3-yl)-butyl ester (3): To a solution of compound 2 (9.5 g, 35.18 mmol) and (S)-piperidine-1,2 dicarboxylic acid 1-tert-butyl ester (12.1 g, 52.78 mmol), and N,N-dimethyl-4-aminopyridine (427 mg, 3.5 mmol) in methylene chloride (CH_2Cl_2 , 50 mL) at 0 °C was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (10.1 g, 52.78 mmol). The reaction was warmed to room temperature and allowed to stir for 16 h. The reaction was diluted with EtOAc, washed with water, 5% aqueous sodium bicarbonate (NaHCO_3), brine, dried over anhydrous magnesium sulfate (MgSO_4) and concentrated to provide 16.67 g of compound 3 as a viscous oil.

Example 4

(S)-Piperidine-2-carboxylic acid 2-(1-(3-pyridin-3-yl-propyl)-4-pyridin-3-yl)-butyl ester (4): To a solution of compound 3 (16.67 g, 34.66 mmol) in CH_2Cl_2 (40 mL) at 0°C was added trifluoroacetic acid (40 mL). After the addition was complete, the reaction was warmed to room temperature and stirred for 4 h. The reaction was concentrated and the residue taken up into water and made basic with solid K_2CO_3 . The product was extracted with CH_2Cl_2 (2x). The extracts were combined dried

- 23 -

over MgSO_4 , filtered and concentrated to provide 13.20 g of compound 4 as a viscous oil.

Example 5

5 (S)-1-((3,4,5-Trimethoxyphenyl)-methyl-carbamoyl)-
piperidine-2-carboxylic acid 4-pyridin-3-yl-1-(3-
pyridin-3-yl-propyl)-butyl ester (5): To a mixture of
N-methyl-3,4,5-trimethoxyaniline (130 mg, 0.66 mmol)
and diisopropylethylamine ($i\text{-Pr}_2\text{NEt}$, 215 μL , 1.2 mmol)
10 in methylene chloride (CH_2Cl_2 , 1 mL) was added 1.2 M
phosgene in toluene (1.65 mL). After stirring for 2 h,
the reaction was concentrated and placed under vacuum
to remove residual phosgene. To a solution of compound
4 (225 mg, 0.59 mmol) in CH_2Cl_2 (1.5 mL) containing $i\text{-Pr}_2\text{EtN}$ (215 μL , 1.2 mmol) was added the above preformed
15 acyl chloride in CH_2Cl_2 (1.5 mL). After stirring for
1 h, the reaction was diluted with ethyl acetate
(EtOAc), washed with 5% aq. NaHCO_3 , brine, dried over
 MgSO_4 , filtered and concentrated in vacuo to provide a
viscous oil. Chromatography of the residue on SiO_2
20 (elution with 30 to 60% acetone:hexanes) provided
238 mg (67%) of compound 5 as a viscous oil. ^1H NMR
(500 MHz, CDCl_3) δ 8.44-8.40 (m, 4H), 7.35 (m, 2H),
7.22-7.18 (m, 2H), 6.43 (br s, 2H), 4.98 (m, 1H), 4.74
(m, 1H), 3.84 (s, 9H), 3.42 (br s, 1H), 3.18 (s, 3H),
25 2.92 (m, 1H), 2.65-2.56 (m, 5H), 2.06-1.98 (m, 1H),
1.70-1.53 (m, 15H).

Example 6

(S)-1-((3-Trifluoromethylphenyl)-methyl-carbamoyl)-
piperidine-2-carboxylic acid 4-pyridin-3-yl-1-(3-
30 pyridin-3-yl-propyl)-butyl ester (6): Compound 6 was
prepared according to the protocol of Example 5, except
that N-methyl-3,4,5-trimethoxyaniline was replaced with
N-methyl-3-trifluoromethylaniline. ^1H NMR (500 MHz,

- 24 -

CDCl₃) δ 8.42-8.39 (m, 4H), 7.50-6.16 (m, 10H), 4.99 (m, 1H), 4.64 (m, 1H), 3.29 (m, 1H), 3.20 (s, 3H), 2.93 (m, 1H), 2.67-2.53 (m, 4H), 2.03-1.99 (m, 1H), 1.69-1.53 (m, 13H).

5

Example 7

(S)-1-((4-Tert-butylphenyl)-methyl-carbamoyl)-piperidine-2-carboxylic acid 4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl ester (7): Compound 7 was prepared according to the protocol of Example 5, except that N-methyl-3,4,5-trimethoxyaniline was replaced with N-methyl-4-tert-butylaniline. ¹H NMR (500 MHz, CDCl₃) δ 8.40 (m, 4H), 7.49-7.42 (m, 2H), 7.30 (d, 2H), 7.17 (m, 2H), 7.05 (d, 2H), 4.99 (m, 1H), 4.64 (m, 1H), 3.35 (m, 1H), 3.14 (s, 3H), 2.84 (dt, 1H), 2.64-2.52 (m, 4H), 2.00-1.95 (m, 1H), 1.70-1.48 (m, 11H), 1.27 (s, 9H), 1.20-1.02 (m, 2H).

15

Example 8

(S)-1-((4-Isopropylphenyl)-methyl-carbamoyl)-piperidine-2-carboxylic acid 4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl ester (8): Compound 8 was prepared according to the protocol of Example 5, except that N-methyl-3,4,5-trimethoxyaniline was replaced with N-methyl-4-iso-propylaniline. ¹H NMR (500 MHz, CDCl₃) δ 8.42-8.39 (m, 4H), 7.49-7.43 (m, 2H), 7.18 (m, 2H), 7.14 (d, 2H), 7.06 (d, 2H), 4.99 (m, 1H), 4.64 (m, 1H), 3.35 (br d, 1H), 3.15 (s, 3H), 2.85 (m, 2H), 2.59 (m, 4H), 1.97 (m, 1H), 1.70-1.49 (m, 11H), 1.21 (d, 6H), 1.20-1.02 (m, 2H).

20

25

Example 9

(S)-1-(Piperidine-1-carbonyl)-piperidine-2-carboxylic acid 4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl ester (9): Compound 9 was prepared according to the

30

- 25 -

protocol of Example 5, except that N-methyl-3,4,5-trimethoxyaniline was replaced with N-piperidine. ¹H NMR (500 MHz, CDCl₃) δ 8.42-8.39 (m, 4H), 7.50-7.43 (m, 2H), 7.24-7.16 (m, 2H), 4.98 (m, 1H), 4.67 (t, 1H), 3.32-3.09 (m, 8H), 2.64-2.52 (m, 6H), 2.01-1.96 (m, 1H), 1.80-1.30 (m, 15H).

Example 10

(S)-1-((3,4,5-Trimethoxyphenyl)-methyl-carbamoyl)-piperidine-2-carboxylic acid 4-pyridin-1-yl-1-(3-pyridin-1-yl-propyl)-butyl ester (10): Compound 10 was prepared according to the protocols of Examples 1-5, except that 3-bromopyridine was replaced with 1-bromopyridine. ¹H NMR (500 MHz, CDCl₃) δ 8.50 (t, 2H), 7.56 (dq, 2H), 7.18-7.08 (m, 4H), 6.43 (s, 2H), 4.97 (q, 1H), 4.78 (m, 1H), 3.83 (s, 9H), 3.44 (br d, 1H), 3.19 (s, 3H), 2.89 (dt, 1H), 2.82-2.73 (m, 4H), 2.07 (br d, 1H), 1.81-1.52 (m, 12H).

Example 11

(S)-Piperidine-1,2-dicarboxylic acid 1-(3,4,5-trimethoxyphenyl) ester 2-(4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl) ester (11): Compound 11 was prepared according to the protocol of Example 5, except that N-methyl-3,4,5-trimethoxyaniline was replaced with 3,4,5-trimethoxyphenol. Compound as a mixture of rotomers: ¹H NMR (500 MHz, CDCl₃) δ 8.42-8.35 (m), 7.50-7.32 (m), 7.28-7.18 (m), 6.34 (s), 6.27 (s), 5.34-4.90 (m), 4.19-4.01 (m), 3.78 (s), 3.75 (s), 3.22 (br dt), 3.14 (quintet), 3.05-2.90 (m), 2.65-2.53 (m), 2.27-2.21 (m), 2.02 (s), 1.80-1.45 (m).

- 26 -

Example 12

(S)-Piperidine-2-carboxylic acid 2-(1-(2-phenyl-ethyl)-3-phenyl-propyl ester (12): Compound 12 was prepared according to the protocols of Examples 3-4, except that compound 2 in Example 3 was replaced with 1,5-diphenylpentan-3-ol.

Example 13

(S)-1-((3,4,5-Trimethoxyphenyl)-methyl-carbamoyl)-piperidine-2-carboxylic acid 1-(2-phenyl-ethyl)-3-phenyl-propyl ester (13): Compound 13 was prepared according to the protocol of Example 5, except that compound 4 was replaced with compound 12. ¹H NMR (500 MHz, CDCl₃) δ 7.27 (m, 4H), 7.20-7.14 (m, 6H), 6.47 (s, 2H), 5.01 (m, 1H), 4.87 (m, 1H), 3.84 (s, 6H), 3.83 (s, 3H), 3.48 (br d, 1H), 3.23 (s, 3H), 2.94 (dt, 1H), 2.72-2.44 (m, 4H), 2.17-2.10 (m, 1H), 2.00-1.85 (m, 4H), 1.67-1.60 (m, 2H), 1.45-1.40 (m, 1H), 1.30-1.18 (m, 2H).

Example 14

4-(Methyl-(2-(1-phenethyl-3-phenyl-propoxycarbonyl)-piperidine-1-carboxyl)-amino)-benzenesulfonic acid (14): Compound 14 was prepared according to the protocol of Example 13, except that N-methyl-3,4,5-trimethoxyaniline was replaced with N-methyl-4-aminophenyl sulfonic acid.

Example 15

(S)-Piperidine-2-carboxylic acid 1-benzylloxymethyl-2-benzylloxethyl ester (15): Compound 15 was prepared according to the protocols of Examples 3-4, except that compound 2 in Example 3 was replaced with 1,3-dibenzyloxypropan-2-ol.

- 27 -

Example 16

(S)-1-(Methyl-(4-morpholin-1-yl-phenyl)-carbamoyl)-piperidine-2-carboxylic acid 2-benzyloxy-1-(benzyloxymethyl)-ethyl ester (16): Compound 16 was prepared according to the protocol of Example 5, except that compound 4 was replaced with compound 15 and N-methyl-3,4,5-trimethoxyaniline with N-methyl-4-morpholinoaniline. ¹H NMR (500 MHz, CDCl₃) δ 7.34-7.11 (m, 10H), 7.09 (d, 2H), 6.84 (d, 2H), 5.29 (quintet, 1H), 4.81 (br t, 1H), 4.54 (d, 2H), 4.49 (dd, 2H), 3.84 (t, 2H), 3.67 (t, 2H), 3.40 (br d, 1H), 3.15 (s, 3H), 3.09 (t, 4H), 2.86 (dt, 1H), 2.08-2.05 (m, 1H), 1.60-1.44 (m, 2H), 1.27-1.08 (m, 3H).

Example 17

(S)-1-(Methyl-(4-piperidin-1-yl-phenyl)-carbamoyl)-piperidine-2-carboxylic acid 2-benzyloxy-1-(benzyloxymethyl)-ethyl ester (17): Compound 17 was prepared according to the protocol of Example 16, except that N-methyl-3,4,5-trimethoxyaniline was replaced with N-methyl-4-piperidinoaniline. ¹H NMR (500 MHz, CDCl₃) δ 7.36-7.25 (m, 10H), 7.06 (d, 2H), 6.86 (d, 2H), 5.29 (quintet, 1H), 4.79 (m, 1H), 4.55-4.48 (m, 4H), 3.66 (m, 4H), 3.41 (br d, 1H), 3.14 (s, 3H), 3.10 (m, 4H), 2.87 (dt, 1H), 2.05 (br d, 1H), 1.73-1.67 (m, 4H), 1.61-1.45 (m, 4H), 1.25-1.08 (m, 3H).

Example 18

(S)-Piperidine-1,2-dicarboxylic acid 2-(2-benzyloxy-1-(benzyloxymethyl)-ethyl)ester 1-quinolin-5-yl ester (18): Compound 18 was prepared according to the protocol of Example 16, except that N-methyl-3,4,5-trimethoxyaniline was replaced with 5-hydroxyquinoline. Compound 18 was a mixture of rotomers: ¹H NMR (500 MHz, CDCl₃) δ 8.89 (dd), 8.86 (dd), 8.90 (d), 8.24

- 28 -

(d), 7.89 (t), 7.67 (t), 7.63 (t), 7.36-7.18 (m), 5.44 (quintet), 5.36 (quintet), 5.20 (d), 5.02 (d), 4.56-4.44 (m), 4.34 (br d), 4.14 (br d), 3.72-3.56 (m), 3.39 (dt), 3.09 (dt), 2.38 (br t), 1.90-1.49 (m), 1.40-1.29 (m).

Example 19

(S)-Piperidine-1,2-dicarboxylic acid 2-(2-benzoyloxy-1-(benzyloxymethyl)-ethyl)ester 1-pyridin-3-yl ester (19): Compound 19 was prepared according to the protocol of Example 16, except that N-methyl-3,4,5-trimethoxyaniline was replaced with 3-hydroxypyridine. Compound 19 was a mixture of rotomers: ¹H NMR (500 MHz, CDCl₃) δ 8.46-8.41 (m), 7.48 (dt), 7.43 (dt), 7.34-7.24 (m), 7.18 (dd), 5.40-5.33 (m), 5.03 (dd), 4.57-4.47 (m), 4.17 (br d), 3.69-3.66 (m), 3.27 (dt), 3.05 (dt), 2.33 (br d), 1.81-1.71 (m), 1.69-1.64 (m), 1.56-1.43 (m), 1.35-1.27 (m).

Example 20

2-(1,3-Dimethyl-3-(3,4,5-trimethoxyphenyl)ureido)-3-phenyl-propanoic acid 4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl ester (20): Compound 20 is prepared according to the protocols of Examples 3-5, by replacing (S)-piperidine-1,2-dicarboxylic acid 1-tert-butyl ester with N-(tert-butoxycarbonyl)-L-phenylalanine.

Example 21

2-(1,3-Dimethyl-3-(3,4,5-trimethoxyphenyl)ureido)-3-(phenyl)-propanoic acid 3-pyridin-3-yl-1-(2-pyridin-3-yl-ethyl)-propyl ester (21): Compound 21 is prepared according to the protocols of Examples 3-5, by replacing (S)-piperidine-1,2-dicarboxylic acid 1-tert-butyl ester with N-(tert-butoxycarbonyl)-L-

- 29 -

phenylalanine and 1,7-dipyridin-3-yl-heptan-4-ol with 1,5-dipyridin-3-yl-pentan-3-ol.

Example 22

5 N-Methyl-2-phenylethylamine-1,2-dicarboxylic acid 1-(3,4,5-trimethoxyphenyl) ester 2-(4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)butyl) ester (22): Compound 22 is prepared according to the protocol of Example 20, by replacing N-methyl-3,4,5-trimethoxyaniline with 3,4,5-trimethoxyphenol.

10

Example 23

N-Methyl-2-phenylethylamine-1,2-dicarboxylic acid 1-(3,4,5-trimethoxyphenyl) ester 2-(3-pyridin-3-yl-1-(2-pyridin-3-yl-ethyl)propyl) ester (23): Compound 23 is prepared according to the protocol of Example 21, by replacing N-methyl-3,4,5-trimethoxyaniline with 3,4,5-trimethoxyphenol.

15

Example 24 -- MDR SENSITIZATION ASSAYS

To assay the ability of the compounds according to this invention to increase the antiproliferative activity of a drug, cell lines which are known to be resistant to a particular drug may be used. These cell lines include, but are not limited to, the L1210, P388D, CHO and MCF7 cell lines. Alternatively, resistant cell lines may be developed. The cell line is exposed to the drug to which it is resistant, or to the test compound; cell viability is then measured and compared to the viability of cells which are exposed to the drug in the presence of the test compound.

20
25
30

We have carried out assays using L1210 mouse leukemia cells transformed with the pHaMDR1/A retrovirus carrying a MDR1 cDNA, as described by Pastan

- 30 -

et al., Proc. Natl. Acad. Sci., Vol. 85, 4486-4490 (1988). The resistant line, labelled L1210VMDRC.06, was obtained from Dr. M. M. Gottesman of the National Cancer Institute. These drug-resistant transfectants
5 had been selected by culturing cells in 0.06 mg/ml colchicine.

Multi-drug resistance assays were conducted by plating cells (2×10^3 , 1×10^4 , or 5×10^4 cells/well) in 96 well microtiter plates and exposing
10 them to a concentration range of doxorubicin (50 nM-10 μ M) in the presence or absence of multi-drug resistance modifier compounds ("MDR inhibitors") of this invention (1, 2.5 or 10 μ M) as described in Ford et al., Cancer Res., Vol. 50, 1748-1756. (1990). After culture for 3
15 days, the viability of cells was quantitated using MTT (Mossman) or XTT dyes to assess mitochondrial function. All determinations were made in replicates of 4 or 8. Also see, Mossman T., J. Immunol. Methods, Vol. 65, 55-63 (1983).

20 Results were determined by comparison of the IC_{50} for doxorubicin alone to the IC_{50} for doxorubicin + MDR inhibitor. An MDR ratio was calculated (IC_{50} Dox/ IC_{50} Dox + Inhibitor) and the integer value used for comparison of compound potencies.

25 In all assays, compounds according to this invention were tested for intrinsic antiproliferative or cytotoxic activity. The results are summarized in Table 1 below. As demonstrated in Table 1, the compounds generally caused <10% cytotoxicity at
30 concentrations of 10 μ M or greater. In Table 1, "NT" indicates that the compound was not tested at the respective concentration.

- 31 -

TABLE 1: Evaluation of Compounds for Reversal of MDR

Compound	IC50 Dox Alone	IC50 Dox + 1 μ M Cpd.	IC50 Dox + 2.5 μ M Cpd.	MDR Ratio 1.0 μ M Cpd.	MDR Ratio (2.5 μ M)	
5						
5	700	250	90	2.8	7.8	
6	950	NT	65	NT	14.6	
7	1000	250	65	4.0	15.4	
8	2250	1200	625	1.9	3.6	
10	9	2250	1800	325	1.3	6.9
10	850	400	85	2.1	7.8	
11	2250	1900	1000	1.2	2.3	
13	1800	600	160	3.0	11.5	
14	2250	1200	625	1.9	3.6	
15	16	800	NT	75	NT	10.7
17	950	NT	70	NT	10.7	
18	950	NT	70	NT	13.6	
CsA	800	60	NT	13.3	NT	

20

EXAMPLE 25Inhibition of MRP-Mediated MDR

In order to demonstrate that the compounds of this invention are effective in reversing MPR-mediated MDR, in addition to P-glycoprotein-mediated MDR, we assayed inhibition in a non-P-glycoprotein expressing cell line.

We plated HL60/ADR cells in 96 well microtiter plates (4×10^4 cells/well). The cells were then exposed to various concentrations of doxorubicin (50 nM to 10 μ M) in the presence or absence of various compounds of this invention at various concentrations (0.5 - 10 μ M). After culturing the cells for 3 days, their viability was quantitated using the XTT dye method to assess mitochondrial function. Results were expressed as a ratio of the IC₅₀ for doxorubicin alone to the the IC₅₀ for doxorubicin plus MDR inhibitor. IC₅₀ values are expressed in nM. In all assays the intrinsic antiproliferative or cytotoxicity activity of

- 32 -

the MDR inhibitors was also determined for HL60/ADR cells. The results of this assay are set forth in Table 2 below:

Table 2: Reversal Of MRP-mediated MDR in HL60/ADR Cells

Cmpd	IC ₅₀ Dox alone	IC ₅₀ Dox + 0.5 μ M Cpd	IC ₅₀ Dox + 1 μ M Cpd	IC ₅₀ Dox + 2.5 μ M Cpd	IC ₅₀ Dox + 5 μ M Cpd	IC ₅₀ Dox + 10 μ M Cpd	MDR Ratio 0.5 μ M	MDR Ratio 1 μ M	MDR Ratio 2.5 μ M	MDR Ratio 5 μ M	MDR Ratio 10 μ M
6	9.0	4	3.2	0.9	0.175	0.09	1.3	1.6	5.6	29.6	53.8
18	9.0	4	3	2.4	1.3	0.9	1.3	1.7	2.1	3.8	5.6


While we have described a number of embodiments of this invention, it is apparent that our basic constructions may be altered to provide other embodiments which utilize the products, processes and methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims, rather than by the specific embodiments which have been presented by way of example.

- 33 -

CLAIMS

I claim:

1. A compound of formula (I):



wherein A is CH₂, oxygen, NH or N-(C1-C4 alkyl);

wherein B and D are independently:

Ar, (C1-C6)-straight or branched alkyl,
 (C2-C6)-straight or branched alkenyl or alkynyl,
 (C5-C7)-cycloalkyl substituted (C1-C6)-straight or
 branched alkyl, (C3-C6)-straight or branched alkenyl or
 alkynyl, (C5-C7)-cycloalkenyl substituted
 (C1-C6)-straight or branched alkyl, (C3-C6)-straight or
 branched alkenyl or alkynyl, Ar-substituted
 (C1-C6)-straight or branched alkyl, Ar-substituted
 (C3-C6)-straight or branched alkenyl or alkynyl,

wherein any one of the CH₂ groups of said
 alkyl chains may be optionally replaced by a heteroatom
 selected from the group consisting of O, S, SO, SO₂,
 and NR, wherein R is selected from the group consisting
 of hydrogen, (C1-C4)-straight or branched alkyl,
 (C3-C4)-straight or branched alkenyl or alkynyl, and
 (C1-C4) bridging alkyl wherein a bridge is formed
 between the nitrogen and a carbon atom of said
 heteroatom-containing chain to form a ring, and wherein
 said ring is optionally fused to an Ar group;

- 34 -

J is selected from the group consisting of hydrogen, (C1-C6)-straight or branched alkyl, (C3-C6)-straight or branched alkenyl and $-\text{CH}_2\text{Ar}$;

K is selected from the group consisting of (C1-C4)-straight or branched alkyl, $-\text{CH}_2\text{Ar}$, and cyclohexylmethyl;

or J and K may be taken together to form a 5-7 membered heterocyclic ring which may contain a heteroatom selected from the group consisting of O, S, SO and SO_2 ;

Z is O or S;

Y is O or N, wherein

when Y is O, then R_1 is a lone pair and R_2 is selected from the group consisting of Ar, (C1-C6)-straight or branched alkyl, and (C3-C6)-straight or branched alkenyl or alkynyl; and

when Y is N, then R_1 and R_2 are independently selected from the group consisting of Ar, (C1-C6)-straight or branched alkyl, and (C3-C6)-straight or branched alkenyl or alkynyl; or R_1 and R_2 are taken together to form a heterocyclic 5-6 membered ring selected from the group consisting of pyrrolidine, imidazolidine, pyrazolidine, piperidine, and piperazine;

wherein Ar is a carbocyclic aromatic group selected from the group consisting of phenyl, 1-naphthyl, 2-naphthyl, indenyl, azulenyl, fluorenyl, and anthracenyl;

or a heterocyclic aromatic group selected from the group consisting of 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, 2-pyrazolinyl, pyrazolidinyl, isoxazolyl, isotriazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, 1,3,4-thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl,

- 35 -

1,3,5-trithianyl, indolizinyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furanyl, benzo[b]thiophenyl, 1H-indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H-quinolizinyl, quinolinyl, 1,2,3,4-tetrahydroquinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, and phenoxazinyl;

wherein Ar may contain one or more substituents which are independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, -SO₃H, trifluoromethyl, trifluoromethoxy, (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, O-[(C1-C6)-straight or branched alkyl], O-[(C3-C4)-straight or branched alkenyl], O-benzyl, O-phenyl, 1,2-methylenedioxy, -NR₃R₄, carboxyl, N-(C1-C5-straight or branched alkyl or C3-C5-straight or branched alkenyl) carboxamides, N,N-di-(C1-C5-straight or branched alkyl or C3-C5-straight or branched alkenyl) carboxamides, morpholinyl, piperidinyl, O-X, CH₂-(CH₂)_q-X, O-(CH₂)_q-X, (CH₂)_q-O-X, and CH=CH-X;

wherein R₃ and R₄ are independently selected from the group consisting of (C1-C6)-straight or branched alkyl, (C3-C6)-straight or branched alkenyl, hydrogen and benzyl, or wherein R₃ and R₄ can be taken together to form a 5-6 membered heterocyclic ring; X is selected from the group consisting of 4-methoxyphenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrazyl, quinolyl, 3,5-dimethylisoxazolyl, isoxazolyl, 2-methylthiazoyl, thiazoyl, 2-thienyl, 3-thienyl, and pyrimidyl; q is 0-2; and

n is 0 or 1.

- 36 -

2. The compound according to claim 1, wherein, in formula (I), J and K are taken together to form a 5-7 membered ring.

3. The compound according to claim 1 or 2, wherein, in formula (I), at least one of B or D is independently represented by the formula $-(CH_2)_r-(X)-(CH_2)_s-Ar$, wherein:

r is 1-4;

s is 0-1;


Ar is as defined in claim 1; and

each X is independently selected from the group consisting of CH_2 , O, S, SO, SO_2 , and NR, wherein R is selected from the group consisting of hydrogen, (C1-C4)-straight or branched alkyl, (C3-C4)-straight or branched alkenyl or alkynyl, and (C1-C4) bridging alkyl wherein a bridge is formed between the nitrogen atom and the Ar group.

4. The compound according to claim 1 or 2, wherein, in formula (I), Ar is selected from the group consisting of phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, indolyl, isoindolyl, quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, and 1,2,3,4-tetrahydroquinolinyl, wherein said Ar may contain one or more substituents which are independently selected from the group consisting of hydrogen, hydroxyl, nitro, trifluoromethyl, (C1-C6)-straight or branched alkyl, O-[(C1-C6)-straight or branched alkyl], halogen, SO_3H , and NR_3R_4 , wherein R_3 and R_4 are independently selected from the group consisting of (C1-C6)-straight or branched alkyl, (C3-C6)-straight or branched alkenyl, hydrogen and benzyl; or wherein R_3 and R_4 can be taken together to form a 5-6 membered heterocyclic ring.


- 37 -

5. A compound of formula (II) or (III):



wherein Y, R₁ and R₂ are as defined in claim 1, Ar is as defined in claim 4 and w is 1 or 2.

6. A compound of formula (II') or (III'):



wherein Y, R₁ and R₂ are as defined in claim 1, Ar is as defined in claim 4, J is hydrogen, (C1-C6)-straight or branched alkyl or (C3-C6)-straight or branched alkenyl, and w is 1 or 2.

7. A compound selected from the group consisting of:

(S)-1-((3,4,5-Trimethoxyphenyl)-methyl-carbamoyl)-piperidine-2-carboxylic acid 4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl ester;

(S)-1-((3-Trifluoromethylphenyl)-methyl-carbamoyl)-piperidine-2-carboxylic acid 4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl ester;

- 38 -

(S)-1-((4-Tert-butylphenyl)-methyl-carbamoyl)-piperidine-2-carboxylic acid 4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl ester;

(S)-1-((4-Isopropylphenyl)-methyl-carbamoyl)-piperidine-2-carboxylic acid 4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl ester;

(S)-1-(Piperidine-1-carbonyl)-piperidine-2-carboxylic acid 4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl ester;

(S)-1-((3,4,5-Trimethoxyphenyl)-methyl-carbamoyl)-piperidine-2-carboxylic acid 4-pyridin-1-yl-1-(3-pyridin-1-yl-propyl)-butyl ester;

(S)-Piperidine-1,2-dicarboxylic acid 1-(3,4,5-trimethoxyphenyl) ester 2-(4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl) ester;

(S)-Piperidine-2-carboxylic acid 2-(1-(2-phenyl-ethyl)-3-phenyl-propyl) ester;

(S)-1-((3,4,5-Trimethoxyphenyl)-methyl-carbamoyl)-piperidine-2-carboxylic acid 1-(2-phenyl-ethyl)-3-phenyl-propyl ester;

4-(Methyl-(2-(1-phenethyl-3-phenyl-propoxycarbonyl)-piperidine-1-carbonyl)-amino)-benzenesulfonic acid;

(S)-Piperidine-2-carboxylic acid 1-benzyloxy-methyl-2-benzyloxyethyl ester;

(S)-1-(Methyl-(4-morpholin-1-yl-phenyl)-carbamoyl)-piperidine-2-carboxylic acid 2-benzyloxy-1-(benzyloxy-methyl)-ethyl ester;

(S)-1-(Methyl-(4-piperidin-1-yl-phenyl)-carbamoyl)-piperidine-2-carboxylic acid 2-benzyloxy-1-(benzyloxy-methyl)-ethyl ester;

(S)-Piperidine-1,2-dicarboxylic acid 2-(2-benzyloxy-1-(benzyloxymethyl)-ethyl)ester 1-quinolin-5-yl ester;

- 39 -

(S)-Piperidine-1,2-dicarboxylic acid 2-(2-benzyloxy-1-(benzyloxymethyl)-ethyl)ester 1-pyridin-3-yl ester; and
pharmaceutically acceptable derivatives thereof.

8. A compound selected from the group consisting of:

2-(1,3-Dimethyl-3-(3,4,5-trimethoxyphenyl)ureido)-3-phenyl-propanoic acid 4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl ester;

2-(1,3-Dimethyl-3-(3,4,5-trimethoxyphenyl)ureido)-3-(phenyl)-propanoic acid 3-pyridin-3-yl-1-(2-pyridin-3-yl-ethyl)-propyl ester;

N-Methyl-2-phenylethylamine-1,2-dicarboxylic acid 1-(3,4,5-trimethoxyphenyl) ester 2-(4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)butyl) ester; and

N-Methyl-2-phenylethylamine-1,2-dicarboxylic acid 1-(3,4,5-trimethoxyphenyl) ester 2-(3-pyridin-3-yl-1-(2-pyridin-3-yl-ethyl)propyl) ester; and
pharmaceutically acceptable derivatives thereof.

9. A pharmaceutical composition for treatment or prevention of multi-drug resistance comprising a pharmaceutically effective amount of a compound according to any one of claims 1 to 8 and a pharmaceutically acceptable carrier, adjuvant or vehicle.

10. The pharmaceutical composition according to claim 9, further comprising a chemotherapeutic agent.

11. The pharmaceutical composition according to claim 9 or 10, further comprising a chemosensitizer,

- 40 -

other than the compound according to any one of claims 1 to 8.

12. A method for treating or preventing multi-drug resistance in a patient comprising the step of administering to said patient a pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to any one of claims 1, 2, 5, 6, 7 or 8, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

13. A method for treating or preventing multi-drug resistance in a patient comprising the step of administering to said patient a pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to claim 3.

14. A method for treating or preventing multi-drug resistance in a patient comprising the step of administering to said patient a pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to claim 4.

15. The method according to claim 12, wherein said composition is administered orally.

16. The method according to claim 13 or 14, wherein said composition is administered orally.

17. The method according to claim 12, wherein said multi-drug resistance is P-glycoprotein-mediated.

18. The method according to claim 12, wherein said multi-drug resistance is MRP-mediated.


- 41 -

19. The method according to claim 13 or 14, wherein said multi-drug resistance is P-glycoprotein-mediated.


20. The method according to claim 13 or 14, wherein said multi-drug resistance is MRP-mediated.

21. A process for the synthesis of a compound of formula (I), as defined in any one of claims 1 to 4, comprising the steps of:

(a) esterifying a protected amino acid of formula (X) with an alcohol of formula (XI):




to give an intermediate of formula (XII):



(b) deprotecting the amino protecting group in the intermediate of formula (XII) to give an amino ester of formula (XIII):


- 42 -



;

and

(c) acylating the free amino group in the compound of formula (XIII) with an acyl halide of formula (XIV):



or an activated derivative thereof;

wherein P is a protecting group and A, B, D, J, K, Y and Z are as defined in claim 1.

22. The process according to claim 21, wherein A and Z are oxygen.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 95/03716

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 12-20 relate to a method of treatment of the human or animal body by therapy; the search has been carried out and based on the alleged effects of the compounds/compositions.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
The vast number of theoretically conceivable compounds resulting from the definition in claims 1-4, 9-22 precludes a comprehensive search. Guided by the descriptive part of the present application the search has been limited to the examples.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be covered without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

National Application No

PCT/US 95/03716

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9301167	21-01-93	FR-A- 2678938	15-01-93
		AT-T- 120732	15-04-95
		AU-A- 2327592	11-02-93
		CA-A- 2102697	11-01-93
		CZ-A- 9400049	13-04-94
		DE-D- 69201956	11-05-95
		EP-A- 0527069	10-02-93
		EP-A- 0593639	27-04-94
		ES-T- 2071510	16-06-95
		JP-T- 6509331	20-10-94
		NO-A- 934300	26-11-93
		NZ-A- 243514	28-03-95
WO-A-9219593	12-11-92	AU-A- 1995792	21-12-92
		CA-A- 2102180	10-11-92
		EP-A- 0584223	02-03-94
		JP-T- 6508125	14-09-94
EP-A-0445796	11-09-91	IL-A- 97401	15-03-95
		JP-A- 4217652	07-08-92
		US-A- 5430024	04-07-95
		US-A- 5273982	28-12-93
EP-A-0393781	24-10-90	AT-T- 118216	15-02-95
		DE-D- 69016688	23-03-95
		ES-T- 2070994	16-06-95
		JP-A- 2292290	03-12-90
		US-A- 5073547	17-12-91
US-A-5284840	08-02-94	GB-A- 2267708	15-12-93
WO-A-9407858	14-04-94	AU-B- 5164893	26-04-94
		CA-A- 2144962	14-04-94
		CN-A- 1088577	29-06-94
		EP-A- 0662958	19-07-95
		FI-A- 951454	27-03-95
		NO-A- 951162	29-05-95

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 95/03716

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D211/60 C07D401/12 C07D401/14 A61K31/44 A61K31/445
 C07C271/54 C07C275/34 C07D213/30 A61K31/47 A61K31/17
 C07D213/65 C07D215/20 A61K31/27

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,93 01167 (RHONE POULENC RORER SA) 21 January 1993 e.g. pages 8-9, formula XI-XIII ---	1,2,4
X	WO,A,92 19593 (VERTEX PHARMACEUTICALS INC) 12 November 1992 e.g. examples on pages 25, 30, 37, 39, 42, 45, 48 ---	1-6,21,22
X	EP,A,0 445 796 (HOFFMANN LA ROCHE) 11 September 1991 see page 14, example 18 ---	1,4
X	EP,A,0 393 781 (SINES) 24 October 1990 see page 7, line 30 ---	1,4
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, etc., definition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

20 July 1995

Date of mailing of the international search report

- 9. 08. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5018 Patents 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tr. 31 651 epo nl,
 Fax (+31-70) 340-2016

Authorized officer

Steendijk, M

INTERNATIONAL SEARCH REPORT

National Application No
PCT/US 95/03716

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US,A,5 284 840 (RUPPRECHT KATHLEEN ET AL) 8 February 1994 see the whole document ---	1-22
P,X	WO,A,94 07858 (VERTEX PHARMA) 14 April 1994	1-6,21, 22
P,X	see the whole document ---	1-22
X	BIOORG. MED. CHEM. LETT., vol. 2,no. 55, 1991 pages 387-390, SCHRICKER ET AL. 'Alpha-chymotrypsin catalyzed (...)' see page 388, compound 4 ---	1,4
X	CHEM. LETT., 1991 pages 81-84, SHONO ET AL. 'Diastereoselective introduction of (...)' see page 82, table 1 -----	1,2,4